✉ Email this page to a colleague
« Back to Dashboard
Pexidartinib hydrochlorideis the generic ingredient in one branded drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Pexidartinib hydrochloride has one hundred and thirty patent family members in forty-one countries.
One supplier is listed for this compound.
Summary for pexidartinib hydrochloride
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||23|
|What excipients (inactive ingredients) are in pexidartinib hydrochloride?||pexidartinib hydrochloride excipients list|
|DailyMed Link:||pexidartinib hydrochloride at DailyMed|
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for pexidartinib hydrochloride
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for pexidartinib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
|Daiichi Sankyo Co., Ltd.||Phase 2|
|Daiichi Sankyo, Inc.||Phase 4|
|Daiichi Sankyo Co., Ltd.||Phase 3|
Pharmacology for pexidartinib hydrochloride
|Drug Class||Kinase Inhibitor|
|Mechanism of Action||Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors|
Cytochrome P450 2B6 Inhibitors
Cytochrome P450 3A Inducers
Tyrosine Kinase Inhibitors
Anatomical Therapeutic Chemical (ATC) Classes for pexidartinib hydrochloride
|Country||Patent Number||Title||Estimated Expiration|
|Taiwan||200827358||Compounds modulating C-FMS and/or C-KIT activity and uses therefor||⤷ Try a Trial|
|World Intellectual Property Organization (WIPO)||2016179415||⤷ Try a Trial|
|Mexico||2009005428||COMPUESTOS QUE MODULAN ACTIVIDAD C-FMS Y/O C-KIT Y USOS PARA ELLO. (COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR.)||⤷ Try a Trial|
|Hong Kong||1248675||調節激酶的1H 吡咯並[2，3-B]吡啶衍生物的合成 (SYNTHESIS OF 1 H-PYRROLO[2,3-B]PYRIDIN DERIVATIVES THAT MODULATE KINASES)||⤷ Try a Trial|
|Australia||2007323644||Compounds modulating c-fms and/or c-kit activity and uses therefor||⤷ Try a Trial|
|Taiwan||I660956||⤷ Try a Trial|
|>Country||>Patent Number||>Title||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.